Not Yet RecruitingNot Applicable

Effect of Continuous Erector Spinae Plane Block With Ropivacaine on Postoperative Pain and NF-κB Levels After Mastectomy

Indonesia40 participantsStarted 2026-05-01

Plain-language summary

This study aims to evaluate the effect of continuous erector spinae plane block (CESPB) using ropivacaine on postoperative pain in patients undergoing elective mastectomy. In addition to pain control, this study investigates the impact of CESPB on systemic inflammatory response as measured by nuclear factor kappa B (NF-κB) levels, opioid consumption, and quality of recovery. Patients will be randomly assigned to receive CESPB or standard analgesia without block. Outcomes will be assessed within the first 24 hours after surgery. The findings are expected to provide evidence on the clinical and biological benefits of CESPB as part of multimodal analgesia in breast surgery.

Who can participate

Age range30 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Female patients aged 18 to 65 years * Diagnosed with breast cancer * Scheduled for elective mastectomy under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Able to understand and provide written informed consent * Body mass index (BMI) 18-29 kg/m² Exclusion Criteria: * Contraindications to regional anesthesia * Contraindications or allergy to ropivacaine or local anesthetics * Inability to use a visual analog scale (VAS) for pain assessment * Inability to understand or operate patient-controlled analgesia (PCA) * History of chronic pain or ongoing infection requiring treatment * History of chronic analgesic use * History of autoimmune disease * Uncontrolled systemic disease

What they're measuring

Postoperative Pain Intensity

Timeframe: 24 hours after surgery

Trial details

NCT IDNCT07562945

SponsorAldy Aldy

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-10-01

Contact for this trial

Aldy Aldy, MD

+6285221222111 aldychen94@gmail.com